Trevena
Trevena is a CNS-focused biopharmaceutical company commercializing the FDA-approved acute-pain drug OLINVYK (oliceridine) and developing three Phase 1 biased-ligand candidates (TRV045, TRV250, TRV734) for CNS disorders.
- Company typePublic
- Founded2007
- HeadquartersKing Of Prussia, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Trevena does
Trevena, Inc. (NASDAQ/Pink Sheets: TRVN) is a biopharmaceutical company founded in 2007 (originally as Parallax Therapeutics, Inc.) and headquartered in Atlanta, GA. It operates as a clinical-stage CNS-focused drug developer built on the proprietary ABLE (Advanced Biased Ligand Explorer) platform, which screens for G protein-coupled receptor (GPCR) biased ligands that selectively activate one signaling pathway (G protein or beta-arrestin) while inhibiting the other. The scientific foundation traces to Nobel laureate Dr. Robert Lefkowitz's GPCR research.
The company's commercial portfolio consists of one FDA-approved product, OLINVYK (oliceridine) injection — an IV mu-receptor biased ligand indicated for acute pain in adults — plus three Phase 1 investigational candidates: TRV045 (S1P receptor, diabetic neuropathic pain and epilepsy), TRV250 (delta receptor, acute migraine), and TRV734 (mu receptor, opioid use disorder). The TRV027 acute-heart-failure program is subject to an exclusive license option held by Forest Laboratories. Trevena has a 51-100 employee organization and reaches acute care hospitals via field sales and medical-affairs channels; its geographic footprint spans the United States and, through Jiangsu Nhwa, China.
Trevena's revenue model combines direct OLINVYK product sales (one-time licensing/transaction structure for institutional acute care), milestone payments and tiered royalties tied to OLINVYK commercial milestones, a non-dilutive royalty-based financing arrangement with R-Bridge Healthcare Fund (CBC Group) covering up to $40 million across US and China rights, and a contingent Forest option on TRV027 that could yield up to $65 million upfront plus $430 million in milestones. Disclosed 2023 revenue was $3.125 million; the company has experienced large operating losses, a reverse stock split in August 2024, and a Nasdaq delisting notification in October 2024, with the stock now trading on Pink Sheets.
Trevena firmographics
Firmographics- Name
- Trevena
- Legal name
- Trevena, Inc.
- Website
- https://trevena.com
- Company type
- Public
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Trevena is a CNS-focused biopharmaceutical company commercializing the FDA-approved acute-pain drug OLINVYK (oliceridine) and developing three Phase 1 biased-ligand candidates (TRV045, TRV250, TRV734) for CNS disorders.
- Ownership category
- akta.pro rank
Trevena industry classification
Industry- Product category
- Specialty Biopharmaceuticals (CNS Therapeutics)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
- akta.pro secondary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Trevena is headquartered
LocationHeadquarters
- HQ city
- King Of Prussia
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Trevena business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Product Sales - OLINVYK: Revenue from commercial sales of OLINVYK (oliceridine) injection in the US market for acute pain management.
- Royalty Financing - R-Bridge Healthcare Fund: Non-dilutive royalty-based financing providing upfront payments and additional payments based on sales milestones and approvals for OLINVYK in China and US markets.
- Milestone Payments: Potential milestone payments of up to $8 million based on US partnership milestones for OLINVYK commercialization.
- Forest Laboratories Option: Potential upfront option exercise fee of $65 million and milestone payments up to $430 million total, plus tiered royalties of 10-20% on net sales if Forest exercises option for TRV027.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Trevena product offering
Product offeringCore offering
Trevena is a biopharmaceutical company that discovers, develops and commercializes GPCR-targeted biased ligands for central nervous system (CNS) disorders. Its commercial offering is OLINVYK (oliceridine) injection, an FDA-approved intravenous analgesic for acute pain in adults, while its development pipeline comprises TRV045 (S1P receptor), TRV250 (delta receptor) and TRV734 (mu receptor)—all Phase 1 candidates. The company leverages its proprietary Advanced Biased Ligand Explorer (ABLE) drug discovery platform to identify biased ligands with potentially improved therapeutic profiles over conventional drugs.
Product overview
Trevena is a biopharmaceutical company focused on developing medicines for central nervous system (CNS) disorders. The company's product portfolio consists of one FDA-approved product—OLINVYK (oliceridine) injection, an intravenous analgesic for acute pain—and three differentiated investigational drug candidates in various phases of clinical development: TRV045 (S1P receptor for diabetic neuropathic pain and epilepsy), TRV250 (delta receptor for acute migraine), and TRV734 (mu receptor for opioid use disorder). The pipeline is built on the company's ABLE (Advanced Biased Ligand Explorer) platform, which enables the discovery of biased ligands that selectively activate specific G-protein coupled receptor signaling pathways to potentially improve therapeutic profiles.
Differentiator
Problem solved
Functional benefit
Brands
- OLINVYK (oliceridine) injection: FDA-approved product for acute pain management, a mu receptor agonist.
Products and services
- OLINVYK (oliceridine) injection OLINVYK is an FDA-approved intravenous mu receptor agonist analgesic for the management of acute pain severe enough to require an opioid analgesic when alternative treatments are inadequate. It was developed using Trevena's biased ligand approach targeting G-protein signaling while minimizing beta-arrestin pathways, marketed to U.S. acute care hospitals and healthcare providers.
- TRV045 TRV045 is an S1P receptor-targeting biased ligand compound in Phase 1 clinical trials being developed for the treatment of diabetic neuropathic pain and epilepsy. It is administered orally.
- TRV250 TRV250 is a delta receptor-targeting compound in Phase 1 clinical development for the acute treatment of migraine. It is administered orally or subcutaneously.
- TRV734 TRV734 is a mu receptor-targeting oral biased ligand in Phase 1 clinical trials for maintenance treatment of opioid use disorder, leveraging Trevena's biased ligand technology platform.
- TRV027 TRV027 is a beta-arrestin biased ligand targeting the AT1R receptor for acute heart failure, currently subject to an exclusive option held by Forest Laboratories Holdings. If exercised, Trevena could receive up to $430 million in milestones plus tiered 10–20% royalties on net sales.
Quantifiable outcome
- TRV130 showed superior analgesia compared to high dose morphine with less respiratory depression, nausea and vomiting in Phase 1b trial
- +1 more outcomes
Companies that use Trevena
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Trevena technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Trevena partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Jiangsu NhwacoreChinese licensee that made first commercial sale of OLINVYK in China, triggering $15 million milestone payment to Trevena. Jiangsu Nhwa is responsible for commercialization of OLINVYK in the Chinese market.
- Forest Laboratories Holdings LimitedcoreForest has exclusive option to license TRV027 for acute heart failure. If Forest exercises option, they receive worldwide development and commercialization rights and Trevena could receive up to $430 million in milestones plus 10-20% royalties on net sales.
Scale indicators7 records
Recent moves8 records
Expansion highlights5 records
Trevena competitors and assessment
Company assessmentDirect peers
- AcelRx Pharmaceuticals: Specialty pharmaceutical company focused on acute pain management with FDA-approved product Dsuvia (sufentanil sublingual). Most directly comparable to Trevena given similar size, single-product focus on hospital-administered analgesics, and recent commercial challenges.
- Collegium Pharmaceutical: Specialty pharmaceutical company commercializing pain products including Xtampza ER and the recently acquired Belbuca. Direct peer in pain specialty pharma with established commercial infrastructure in the same hospital/prescriber channels as OLINVYK.
- Heron Therapeutics: Specialty pharmaceutical company with FDA-approved pain and supportive care products (Cinvanti, Zynrelef). Similar size, specialty focus, and product portfolio depth to Trevena's OLINVYK-driven business.
- Cara Therapeutics: Clinical-stage biopharmaceutical company developing novel pain therapeutics including Korsuva (difelikefalin). Highly comparable as a small-cap CNS/pain biopharma with differentiated mechanism and pipeline of pain indications.
- Tonix Pharmaceuticals: Clinical-stage CNS specialty pharmaceutical company developing treatments for migraine, fibromyalgia, and other CNS disorders. Comparable size, similar CNS focus, and similar early-stage pipeline profile to Trevena.
Broad incumbents
- Acadia Pharmaceuticals: Established CNS specialty pharmaceutical company with commercial products (Nuplazid, Daybue). Comparable therapeutic focus on CNS disorders but with significantly greater scale, multiple approved products, and broader commercial reach than Trevena.
- Supernus Pharmaceuticals: CNS-focused specialty pharmaceutical company with multiple approved products in neurology (Trokendi XR, Oxtellar XR, Qelbree). Operates in similar CNS therapeutic categories but with established commercial portfolio and broader pipeline.
- Vertex Pharmaceuticals: Large-cap biopharmaceutical company that recently received FDA approval for Journavx (suzetrigine), a novel non-opioid acute pain therapeutic. Competes directly with OLINVYK in the acute pain space with significantly greater resources and commercial scale.
Emerging players
- BioXcel Therapeutics: Clinical-stage biopharmaceutical company using AI-driven drug discovery for CNS and immuno-oncology indications. Similar small-cap, CNS-focused profile with early-stage pipeline assets.
- Neumora Therapeutics: Clinical-stage biopharmaceutical company developing precision medicines for neuroscience diseases. Comparable CNS therapeutic focus with similar small-cap, pipeline-driven profile to Trevena.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Trevena social profiles
Digital presenceTrevena financial estimates
Financial estimateRevenue estimate
Valuation estimate
Trevena leadership team
Management profileNumber of profiles
Profiles10 records
Trevena funding detail
Funding detailFunding overview
Funding rounds19 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Trevena M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Trevena
What does Trevena do?
Trevena is a biopharmaceutical company that discovers, develops and commercializes GPCR-targeted biased ligands for central nervous system (CNS) disorders. Its commercial offering is OLINVYK (oliceridine) injection, an FDA-approved intravenous analgesic for acute pain in adults, while its development pipeline comprises TRV045 (S1P receptor), TRV250 (delta receptor) and TRV734 (mu receptor)—all Phase 1 candidates. The company leverages its proprietary Advanced Biased Ligand Explorer (ABLE) drug discovery platform to identify biased ligands with potentially improved therapeutic profiles over conventional drugs.
Is Trevena a public or private company?
Trevena is a public company. It is classified as public and is currently operating.
When was Trevena founded?
Trevena was founded in 2007. It employs 51 to 100 people.
Where is Trevena based?
Trevena is headquartered in King Of Prussia, United States, in the North America region.
How does Trevena make money?
Four revenue lines are on record. Product Sales - OLINVYK is the primary driver. The others are royalty Financing - R-Bridge Healthcare Fund, milestone Payments and forest Laboratories Option.
Who are Trevena's main competitors?
Direct peers on record are AcelRx Pharmaceuticals, Collegium Pharmaceutical, Heron Therapeutics, Cara Therapeutics and Tonix Pharmaceuticals. Broad incumbents are Acadia Pharmaceuticals, Supernus Pharmaceuticals and Vertex Pharmaceuticals. Emerging players are BioXcel Therapeutics and Neumora Therapeutics.
Does Trevena have an API?
No public API is recorded for Trevena.
What industry is Trevena in?
Trevena's product category is Specialty Biopharmaceuticals (CNS Therapeutics). Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its SIC code is 2834.